Ranbaxy's Patent Litigations in the United States

Ranbaxy's Patent Litigations in the United States
Case Code: ECON015
Case Length: 14 Pages
Period: 1993-2005
Pub Date: 2006
Teaching Note: Not Available
Price: Rs.300
Organization : Ranbaxy Laboratories Limited
Industry : Pharmaceutical
Countries : USA
Themes: Corporate Social Responsibility
Ranbaxy's Patent Litigations in the United States
Abstract Case Intro 1 Case Intro 2 Excerpts

Abstract

The case focuses on Ranbaxy Laboratories Limited's patent litigations in the US. It elaborates on the factors that led to the company's global expansion, focusing specifically on the US market. The case discuses in detail Ranbaxy's approach to the US market and also discusses its initial successes. It also looks at the US pharmaceutical industry and the patent system in the US in detail. The Hatch-Waxman Act of 1984 and its significant impact on the generics pharma industry in the US are also explained. The case discusses the problems faced by the generics players in the US in the extremely competitive generics market and the effect of increasing patent litigation costs involved in challenging patent holders. It ends with a note on Ranbaxy's challenges in meeting its target of $ 2 billion for the year 2007.

Issues

The case is structured to achieve the following teaching objectives:

  • Growth strategy of a pharmaceutical company in the international market
  • Benefits and downside of adopting of an inorganic growth strategy in an international market
  • Nature and scope of the US pharmaceutical industry
  • Legal and regulatory environment in the US
  • How patent litigations can be the strategy of choice of generics players for revenue growth
  • Impact of patent litigations on generics players as well as on patent holding companies

Contents

Keywords

Ranbaxy Laboratories Limited, Pfizer, Lipitor, Teva Pharmaceuticals USA Inc., Glaxo Wellcome, Patent Litigations, Drug Price Control Order, Indian Patent Act of 1970, Ranbaxy Pharmaceuticals Inc., Food and Drug Administration (FDA), Generics, Patent and Trademark Office, Pharmaceutical Industry, Hatch-Waxman Act, Abbreviated New Drug Application, Paragraph IV (Para IV) certification, Eli Lilly, Cefaclor, Patent, Dr. Reddy's Laboratories

Buy this case study (Please select any one of the payment options)

Price: Rs.300
 Price: Rs.300
 PayPal (7 USD)

Custom Search